Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Parkinsons Dis ; 12(7): 2135-2146, 2022.
Article in English | MEDLINE | ID: mdl-36057833

ABSTRACT

BACKGROUND: Neurofilament light is a marker of axonal degeneration, whose measurement from peripheral blood was recently made possible by new assays. OBJECTIVE: We aimed to determine whether plasma neurofilament light chain (NfL) concentration reflects brain white matter integrity in patients with early Parkinson's disease (PD). METHODS: 137 early PD patients and 51 healthy controls were included. Plasma NfL levels were measured using ultrasensitive single molecule array. 3T MRI including diffusion tensor imaging was acquired for voxelwise analysis of association between NfL and both fractional anisotropy (FA) and mean diffusivity (MD) in white matter tracts and subcortical nuclei. RESULTS: A pattern of brain microstructural changes consistent with neurodegeneration was associated with increased plasma NfL in most of the frontal lobe and right internal capsule, with decreased FA and increased MD. The same clusters were also associated with poorer global cognition. A significant cluster in the left putamen was associated with increased NfL, with a significantly greater effect in PD than controls. CONCLUSION: Plasma NfL may be associated with brain microstructure, as measured using diffusion tensor imaging, in patients with early PD. Higher plasma NfL was associated with a frontal pattern of neurodegeneration that also correlates with cognitive performance in our cohort. This may support a future role for plasma NfL as an accessible biomarker for neurodegeneration and cognitive dysfunction in PD.


Subject(s)
Diffusion Tensor Imaging , Parkinson Disease , Biomarkers , Diffusion Tensor Imaging/methods , Humans , Intermediate Filaments , Magnetic Resonance Imaging , Neurofilament Proteins , Parkinson Disease/complications , Parkinson Disease/diagnostic imaging
2.
J Parkinsons Dis ; 12(3): 865-870, 2022.
Article in English | MEDLINE | ID: mdl-35068417

ABSTRACT

The alpha-synuclein gene promoter (SNCA-Rep1) is associated with Parkinson's disease (PD), but its relationship with performance across individual cognitive domains in early PD is unknown. This study aims to investigate Rep1 polymorphism and longitudinal change in cognition in early PD. In this longitudinal study, Rep1 allele lengths ("long" and "short") were determined in 204 early PD patients. All participants underwent annual neuropsychological assessments and followed up for 3 years. Linear-mixed model was performed to investigate the association of Rep1 status and longitudinal change in individual cognitive domains. At 3 years, significant decline in executive function was observed in long Rep1 allele carriers vs short allele carriers, controlling for potential confounders. This is the first longitudinal study demonstrating that long Rep1 allele carriers are at higher risk for executive dysfunction in early PD.


Subject(s)
Parkinson Disease , alpha-Synuclein , Executive Function , Genetic Predisposition to Disease , Humans , Longitudinal Studies , Parkinson Disease/complications , Parkinson Disease/genetics , Polymorphism, Genetic , alpha-Synuclein/genetics
3.
Front Neurol ; 12: 704906, 2021.
Article in English | MEDLINE | ID: mdl-34630281

ABSTRACT

Background: Various classifications have been proposed to subtype Parkinson's disease (PD) based on their motor phenotypes. However, the stability of these subtypes has not been properly evaluated. Objective: The goal of this study was to understand the distribution of PD motor subtypes, their stability over time, and baseline factors that predicted subtype stability. Methods: Participants (n = 170) from two prospective cohorts were included: the Early PD Longitudinal Singapore (PALS) study and the National Neuroscience Institute Movement Disorders Database. Early PD patients were classified into tremor-dominant (TD), postural instability and gait difficulty (PIGD), and indeterminate subtypes according to the Movement Disorder Society's Unified PD Rating Scale (MDS-UPDRS) criteria and clinically evaluated for three consecutive years. Results: At baseline, 60.6% patients were TD, 12.4% patients were indeterminate, and 27.1% patients were PIGD subtypes (p < 0.05). After 3 years, only 62% of patients in TD and 50% of patients in PIGD subtypes remained stable. The mean levodopa equivalent daily dose (LEDD) was higher in the PIGD subtype (276.92 ± 232.91 mg; p = 0.01). Lower LEDD [p < 0.05, odds ratio (OR) 0.99, 95% confidence interval (CI): 0.98-0.99] and higher TD/PIGD ratios (p < 0.05, OR 1.77, 95% CI: 1.29-2.43) were independent predictors of stability of TD subtype with an area under the curve (AUC) of 0.787 (95%CI: 0.669-0.876), sensitivity = 57.8%, and specificity = 89.7%. Conclusion: Only 50-62% of PD motor subtypes as defined by MDS-UPDRS remained stable over 3 years. TD/PIGD ratio and baseline LEDD were independent predictors for TD subtype stability over 3 years.

4.
J Parkinsons Dis ; 10(3): 1231-1237, 2020.
Article in English | MEDLINE | ID: mdl-32310187

ABSTRACT

BACKGROUND: Mild parkinsonian signs (MPS) are common in the older adult and associated with a wide range of adverse health outcomes. There is limited data on the prevalence of MPS and its significance. OBJECTIVE: To determine the prevalence of MPS in the community ambulant population and to evaluate the relationship of MPS with prodromal features of Parkinson's disease (PD) and cognition. METHODS: This cross-sectional community-based study involved participants aged ≥50 years. Parkinsonian signs were assessed using the modified Unified Parkinson's Disease Rating Scale (mUPDRS) and cognition using the Montreal Cognitive Assessment (MoCA). Premotor symptoms of PD were screened using a self-reported questionnaire. Linear regression was used to assess the association of MPS with premotor symptoms of PD and cognitive impairment. RESULTS: Of 392 eligible participants, MPS was present in 105 (26.8%). Mean age of participants with MPS was 68.8±6.9 years and without MPS was 66.1±5.9 years (p < 0.001). Multivariate analysis revealed that MoCA scores were significantly lower in the MPS group (ß= -0.152, 95% CI = -0.009, -0.138, p < 0.05). A significant correlation between the presence of REM sleep behavior disorder (RBD) and total MPS scores (ß= 0.107, 95% CI = 0.053, 1.490, p < 0.05) was also found. Neither vascular risk factors nor other premotor symptoms were significantly associated with MPS. CONCLUSION: MPS is common and closely related to cognitive impairment and increasing age. Presence of RBD is predictive of higher MPS scores. This study highlights the necessity of other investigations or sensitive risk markers to identify subjects at future risk of PD.


Subject(s)
Cognitive Dysfunction/epidemiology , Independent Living/statistics & numerical data , Parkinson Disease/epidemiology , Prodromal Symptoms , REM Sleep Behavior Disorder/epidemiology , Age Factors , Aged , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/etiology , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Parkinson Disease/complications , Parkinson Disease/diagnosis , Prevalence , REM Sleep Behavior Disorder/diagnosis , REM Sleep Behavior Disorder/etiology , Risk Factors , Severity of Illness Index
5.
Mov Disord ; 34(8): 1232-1236, 2019 08.
Article in English | MEDLINE | ID: mdl-31234238

ABSTRACT

BACKGROUND: While the association between alpha-synuclein gene promoter (Rep1) variability and risk of PD is well established, its association with cognition is unclear. OBJECTIVES: To investigate the association between Rep1 and motor and cognitive outcomes in PD. METHODS: Rep1 allele lengths were determined in 172 PD patients who were grouped into "long" and "short" carriers according to previous methods. Multivariable regression analysis was performed to investigate the effect of Rep1 length on cognitive and motor scores. RESULTS: Long Rep1 allele carriers had significantly lower MMSE (P = 0.010) and higher UPDRS Part III (P = 0.026) and H & Y (P = 0.008) scores compared to short allele carriers (controlled for age, sex, and disease duration). Interaction analyses of Rep1 with apolipoprotein 4 revealed no significant effect on clinical outcomes. CONCLUSIONS: PD patients carrying long Rep1 alleles are more impaired on cognitive and motor function independent of apolipoprotein 4 genotype. © 2019 International Parkinson and Movement Disorder Society.


Subject(s)
Cognitive Dysfunction/genetics , Parkinson Disease/genetics , alpha-Synuclein/genetics , Adult , Aged , Aged, 80 and over , Alleles , Apolipoprotein E4/genetics , Cognitive Dysfunction/physiopathology , Cognitive Dysfunction/psychology , Female , Humans , Male , Microsatellite Repeats/genetics , Middle Aged , Parkinson Disease/physiopathology , Parkinson Disease/psychology , Promoter Regions, Genetic/genetics
6.
Ann Clin Transl Neurol ; 6(3): 615-619, 2019 03.
Article in English | MEDLINE | ID: mdl-30911585

ABSTRACT

We utilized ultrasensitive single molecule technology to measure plasma alpha-synuclein in 221 subjects (51 controls, 170 PD). Plasma alpha-synuclein levels were significantly higher in PD than controls (15506.3 vs. 13057.0 pg/mL, P = 0.037), adjusting for age and gender. In PD, alpha-synuclein levels did not vary by H&Y stage or UPDRS motor scores but were significantly higher in PD patients with poorer cognition (MMSE ≤ 25) than controls (P = 0.016, Bonferroni corrected P = 0.047). Alpha-synuclein levels quantified using ultrasensitive single molecule technology discriminate PD from controls and correlate with cognitive severity. These preliminary findings require independent validation to determine the utility of this assay.


Subject(s)
Parkinson Disease/diagnosis , Single Molecule Imaging/methods , alpha-Synuclein/blood , Aged , Female , Humans , Male , Middle Aged , Parkinson Disease/blood , Plasma
7.
Sci Rep ; 6: 35601, 2016 10 20.
Article in English | MEDLINE | ID: mdl-27762307

ABSTRACT

Parkinson's disease (PD) is a debilitating neurodegenerative disorder. Findings on specific white matter (WM) alterations in PD have been inconsistent. We hypothesized that WM changes occur in early PD patients and unbiased whole-brain analysis may provide additional evidence of pathological WM changes in PD. In this study, we examined various indexes of WM microstructure in newly diagnosed PD patients at the whole-brain level. 64 PDs with Hoehn &Yahr stage 1 (HY1PDs), 87 PDs with Hoehn &Yahr stage 2 (HYPD2s), and 60 controls (HCs) were recruited. Tract-based spatial statistics (TBSS) and diffusion connectometry were used to identify changes of WM pathways associated with PD. There were no significant differences in axial diffusivity, but HY1PDs exhibited greater fractional anisotropy (FA) and decreased mean and radial diffusivities (MD and RD) in callosal, projection, and association fibres than HCs and HY2PDs. Motor severity was inversely correlated with FA, but positively correlated with MD and RD in PD patients. Connectometry analysis also revealed increased WM density in the aforementioned tracts in PD patients, compared with HCs. Our study reveals WM enhancement, suggesting neural compensations in early PD. Longitudinal follow-up studies are warranted to identify the trajectory of WM changes alongside the progression of PD.


Subject(s)
Brain/pathology , Parkinson Disease/pathology , White Matter/pathology , Aged , Brain/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Parkinson Disease/diagnostic imaging , White Matter/diagnostic imaging
8.
Parkinsonism Relat Disord ; 24: 63-8, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26810915

ABSTRACT

INTRODUCTION: Excessive daytime sleepiness (EDS) is a common non-motor symptom in Parkinson's disease (PD), but its neuropathology remains elusive due to the limited studies and the inclusion of medicated patients. This current study examined the neural substrates of EDS in drug naïve PD patients. METHODS: A total of 76 PD patients in the early disease stages were recruited; 16 of them had EDS, while the remaining 60 did not. Resting state functional magnetic resonance imaging (rs-fMRI) was used to determine group differences (patients with EDS vs. patients without EDS) in spontaneous neural activity indicated by regional homogeneity (ReHo). Additionally, functional connectivity (FC) of the regions showing group differences in ReHo with the entire brain was performed. RESULTS: ReHo analysis controlling for gray matter volume, age, gender, general cognition, depression, postural instability gait difficulty, and rapid eye movement sleep behavior disorder showed decreased ReHo in the left cerebellum and inferior frontal gyrus, but increased ReHo in the left paracentral lobule in PD-EDS patients, compared with patients without EDS. FC analysis controlling for the same variables as in the analysis of ReHo revealed that the three regions showing ReHo differences had decreased FC with regions in the frontal, temporal, insular and limbic lobes and cerebellum in PDs with EDS. CONCLUSION: While decreases in ReHo and FC were found, increases in ReHo were also noted, implying both neural downregulation and compensatory mechanisms in early PD patients with EDS. Longitudinal studies are warranted to clarify the long-term impact of EDS in PD.


Subject(s)
Brain Mapping , Brain/diagnostic imaging , Disorders of Excessive Somnolence/diagnostic imaging , Disorders of Excessive Somnolence/etiology , Magnetic Resonance Imaging , Parkinson Disease/complications , Rest , Aged , Female , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Oxygen/blood , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL